RS50602B - 8-hidroksi-5-[(1r)-1-hidroksi-2-[[(1r)-2-(4-metoksifenil)-1-metiletil]amino]etil-2(1h)-hinolinon monohidrohlorid u kristalnoj formi i postupka za njegovu pripremu - Google Patents

8-hidroksi-5-[(1r)-1-hidroksi-2-[[(1r)-2-(4-metoksifenil)-1-metiletil]amino]etil-2(1h)-hinolinon monohidrohlorid u kristalnoj formi i postupka za njegovu pripremu

Info

Publication number
RS50602B
RS50602B RSP-2008/0393A RSP20080393A RS50602B RS 50602 B RS50602 B RS 50602B RS P20080393 A RSP20080393 A RS P20080393A RS 50602 B RS50602 B RS 50602B
Authority
RS
Serbia
Prior art keywords
hydroxy
methylethyl
methoxyphenyl
ethyl
amino
Prior art date
Application number
RSP-2008/0393A
Other languages
English (en)
Inventor
Fausto Pivetti
Roberto Pighi
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50602(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of RS50602B publication Critical patent/RS50602B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Postupak za pripremu 8-hidroksi-5-[(1R)-1-hidroksi-2-[[(1R)-2-(4-metoksifenil)-1-metiletil]ami- no]etil]-2(1H)-hinolinon mono-hidrohlorida (I) koji podrazumeva kristalizaciju ili rekristalizaciju jedinjenja (I) od smeše etanol-voda u odnosu od 97:3 do 95:5 u koju se dodaje diizopropil etar, kod koga se smeša etanol-voda koncentriše pod redukovanim pritiskom na temperaturi između 30 i 55° C do zapremine između 1/2 i 1/3 od prvobitne zapremine, a dodavanje diizopropil etra se vrši tokom najmanje 5 minuta. Prijava sadrži još 5 zavisnih patentnih zahteva.
RSP-2008/0393A 2004-03-24 2005-03-24 8-hidroksi-5-[(1r)-1-hidroksi-2-[[(1r)-2-(4-metoksifenil)-1-metiletil]amino]etil-2(1h)-hinolinon monohidrohlorid u kristalnoj formi i postupka za njegovu pripremu RS50602B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
RS50602B true RS50602B (sr) 2010-05-07

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0393A RS50602B (sr) 2004-03-24 2005-03-24 8-hidroksi-5-[(1r)-1-hidroksi-2-[[(1r)-2-(4-metoksifenil)-1-metiletil]amino]etil-2(1h)-hinolinon monohidrohlorid u kristalnoj formi i postupka za njegovu pripremu

Country Status (30)

Country Link
US (1) US20070197586A1 (sr)
EP (1) EP1729773B1 (sr)
JP (1) JP2007530489A (sr)
KR (1) KR20070001946A (sr)
CN (2) CN1929840B (sr)
AR (1) AR048339A1 (sr)
AT (1) ATE399552T1 (sr)
AU (1) AU2005224032A1 (sr)
BR (1) BRPI0508213A (sr)
CA (1) CA2560650A1 (sr)
CY (1) CY1108323T1 (sr)
DE (1) DE602005007871D1 (sr)
DK (1) DK1729773T3 (sr)
EA (1) EA010128B1 (sr)
ES (1) ES2309739T3 (sr)
HR (1) HRP20080495T3 (sr)
IL (1) IL178227A0 (sr)
MA (1) MA28549B1 (sr)
MX (1) MXPA06010515A (sr)
NO (1) NO20064274L (sr)
NZ (1) NZ550010A (sr)
PE (1) PE20060159A1 (sr)
PL (1) PL1729773T3 (sr)
PT (1) PT1729773E (sr)
RS (1) RS50602B (sr)
SI (1) SI1729773T1 (sr)
TN (1) TNSN06249A1 (sr)
UA (1) UA86221C2 (sr)
WO (1) WO2005089760A1 (sr)
ZA (1) ZA200607907B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO2005013945A2 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride

Also Published As

Publication number Publication date
US20070197586A1 (en) 2007-08-23
JP2007530489A (ja) 2007-11-01
ZA200607907B (en) 2008-04-30
CN1929840B (zh) 2010-12-08
AR048339A1 (es) 2006-04-19
AU2005224032A1 (en) 2005-09-29
CA2560650A1 (en) 2005-09-29
DE602005007871D1 (de) 2008-08-14
UA86221C2 (en) 2009-04-10
CY1108323T1 (el) 2014-02-12
DK1729773T3 (da) 2008-10-20
KR20070001946A (ko) 2007-01-04
ATE399552T1 (de) 2008-07-15
ES2309739T3 (es) 2008-12-16
EP1729773A1 (en) 2006-12-13
NO20064274L (no) 2006-10-13
SI1729773T1 (sl) 2008-10-31
MXPA06010515A (es) 2007-03-30
PT1729773E (pt) 2008-09-29
WO2005089760A1 (en) 2005-09-29
PL1729773T3 (pl) 2008-12-31
EA010128B1 (ru) 2008-06-30
EP1729773B1 (en) 2008-07-02
CN101812017A (zh) 2010-08-25
IL178227A0 (en) 2006-12-31
CN1929840A (zh) 2007-03-14
HRP20080495T3 (en) 2008-11-30
BRPI0508213A (pt) 2007-07-17
EA200601531A1 (ru) 2007-04-27
NZ550010A (en) 2010-08-27
MA28549B1 (fr) 2007-04-03
PE20060159A1 (es) 2006-04-04
TNSN06249A1 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
RS50602B (sr) 8-hidroksi-5-[(1r)-1-hidroksi-2-[[(1r)-2-(4-metoksifenil)-1-metiletil]amino]etil-2(1h)-hinolinon monohidrohlorid u kristalnoj formi i postupka za njegovu pripremu
HRP20120190A8 (en) Quinoline derivatives and their use as mycobacterial inhibitors
WO2008047229A3 (en) Biaryl ether urea compounds
MY141224A (en) Crystalline form of a biphenyl compound
DK1831169T3 (da) Fremgangsmåde til fremstilling af et 2-pyridylethylcarboxamidderivat
PE20050348A1 (es) Metanosulfonato del ester etilico del acido 3-[ (2-{ [4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil} -1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino] -propionico
NO20054452D0 (no) Fremgangsmate for fremstilling av 5-[(R)-2-(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist
MA26983A1 (fr) Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
EA200601620A1 (ru) 5,6-диалкил-7-аминотриазолопиримидины, способ их получения и их применение для борьбы с патогенными растениями, а также содержащие их средства
EP3372081A3 (en) Use of fluopyram for controlling nematodes in crops
RS53627B1 (sr) Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze
AR029857A1 (es) Derivados de acidos sulfonil-amino-metil-benzoicos sustituidos y procedimiento para su preparacion
WO2004037212A3 (en) Compositions comprising zopiclone derivatives and methods of making and using the same
RU2007121502A (ru) Способ получения энантиомеров амидоацетонитрильных соединений из их рацематов
HRP20171425T1 (hr) Derivati oksazolidin-2-on-pirimidina
RS51226B (sr) Derivati azapeptida kao inhibitori hiv proteaze
CA2495960A1 (fr) Nouveau procede de synthese du (7-methoxy-1-naphtyl)acetonitrile et application a la synthese de l'agomelatine
HRP20090236T1 (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof and the therapeutic application of the same
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
EA200900926A1 (ru) Способ получения моногидрохлорида 8-гидрокси-5-[(1r)-1-гидрокси-2[[(1r)-2-(4-метоксифенил)-1-метилэтил]амино]этил]-2(1h)-хинолинона
ATE398612T1 (de) Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine
EA202192167A1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы
WO2008089436A3 (en) Crystalline forms of histone deacetylase inhibitors
HK1101398A1 (en) Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2- methoxy-quinoline